Lapatinib, a small-molecule TKI targeting the intracellular tyrosine kinase domain of EGFR and HER2, was found to improve time to progression in HER2 breast cancer patients who had progressed to tratuzumab [7]. Here, EGFR is linked to breast carcinoma.